Theravance Biopharma, Inc.
NASDAQ:TBPH
9.86 (USD) • At close December 26, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 57.424 | 51.346 | 55.311 | 71.857 | 73.414 | 60.37 | 15.386 | 48.648 | 42.126 | 11.688 | 0.226 | 130.145 | 14.854 |
| Cost of Revenue
| 40.621 | 6.589 | 7.286 | 260.953 | 219.248 | 0.715 | 6.03 | 2.894 | 4.657 | 4.058 | 120.579 | 113.995 | 3.844 |
| Gross Profit
| 16.803 | 44.757 | 48.025 | -189.096 | -145.834 | 59.655 | 9.356 | 45.754 | 37.469 | 7.63 | -120.353 | 16.15 | 11.01 |
| Gross Profit Ratio
| 0.293 | 0.872 | 0.868 | -2.632 | -1.986 | 0.988 | 0.608 | 0.941 | 0.889 | 0.653 | -532.535 | 0.124 | 0.741 |
| Reseach & Development Expenses
| 40.621 | 63.392 | 193.657 | 260.953 | 219.248 | 201.348 | 173.887 | 141.712 | 129.165 | 168.522 | 120.579 | 113.995 | 98.85 |
| General & Administrative Expenses
| 64.995 | 59.073 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 5.1 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 70.095 | 67.073 | 99.296 | 108.661 | 106.081 | 97.058 | 95.592 | 84.509 | 90.203 | 71.647 | 35.931 | 25.725 | 21.495 |
| Other Expenses
| 0 | 0 | 0 | -1.61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 113.459 | 130.465 | 292.953 | 369.614 | 325.329 | 298.406 | 269.479 | 226.221 | 219.368 | 240.169 | 156.51 | 139.72 | 120.345 |
| Operating Income
| -56.035 | -91.957 | -257.784 | -297.757 | -251.915 | -238.751 | -260.123 | -180.467 | -181.899 | -232.539 | -156.284 | -9.575 | -109.335 |
| Operating Income Ratio
| -0.976 | -1.791 | -4.661 | -4.144 | -3.431 | -3.955 | -16.906 | -3.71 | -4.318 | -19.896 | -691.522 | -0.074 | -7.361 |
| Total Other Income Expenses Net
| 6.766 | -0.858 | -7.438 | 11.22 | 10.238 | 12.666 | -11.588 | -0.092 | 0.631 | 1.865 | 0 | 0 | 0 |
| Income Before Tax
| -49.269 | -92.815 | -199.577 | -286.537 | -241.677 | -226.085 | -271.711 | -180.559 | -181.268 | -230.674 | -156.284 | -9.575 | -109.335 |
| Income Before Tax Ratio
| -0.858 | -1.808 | -3.608 | -3.988 | -3.292 | -3.745 | -17.66 | -3.712 | -4.303 | -19.736 | -691.522 | -0.074 | -7.361 |
| Income Tax Expense
| 5.924 | 0.009 | -0.151 | -8.52 | -5.222 | -10.561 | 13.694 | 10.11 | 0.951 | 6.364 | 0 | 0 | 0 |
| Net Income
| -55.193 | -92.824 | -199.426 | -278.017 | -236.455 | -215.524 | -285.405 | -190.669 | -182.219 | -237.038 | -156.284 | -9.575 | -109.335 |
| Net Income Ratio
| -0.961 | -1.808 | -3.606 | -3.869 | -3.221 | -3.57 | -18.55 | -3.919 | -4.326 | -20.28 | -691.522 | -0.074 | -7.361 |
| EPS
| -1 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.92 | -0.3 | -3.43 |
| EPS Diluted
| -1 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.84 | -0.3 | -3.43 |
| EBITDA
| -40.867 | -79.857 | -249.389 | -293.999 | -203.291 | -212.437 | -259.137 | -176.036 | -178.768 | -228.012 | -153.631 | -6.324 | -105.491 |
| EBITDA Ratio
| -0.712 | -1.374 | -2.396 | -3.152 | -2.858 | -3.571 | -16.584 | -3.683 | -4.247 | -19.896 | -679.783 | -0.049 | -7.102 |